Your Clinical Development AI Lead Should Come From Trial Operations

What Does a Clinical Development AI Lead Actually Own?

A feasibility model built by the data science group says three of your twelve countries will miss their enrollment curve. Nobody in the room can say what it was trained on, the study team is already six weeks into country contracting, and the medical director wants to know whether to believe it. A clinical development AI lead owns exactly that gap: which AI touches a trial, on what evidence, and who signs.

The first trait to look for is a habit of asking what a model would change about a decision before asking how accurate it is. The tell that separates a real candidate from a performed one is which vocabulary they reach for under pressure. A performed candidate answers in vendor language: platforms, pipelines, agents, a maturity model. A real one answers in protocol amendments, screen failure rate, query rate per subject, time to database lock, and the specific week in a study where the decision gets made. Ask about a project that did not ship. The real ones have several and can say what they misjudged.

The second trait is the ability to draw the line between decision support and anything that reaches a regulatory submission, without hedging. Those two need different evidence, different documentation and different people, and a candidate who blurs them will let the first one drift into the second. Expect them to describe validation as somebody's job with a name attached, usually a GxP AI validation specialist, rather than as a checkbox in their own plan.

The third is that they carry sponsor oversight themselves instead of pointing at a vendor. ICH E6(R3) frames good clinical practice around risk-proportionate quality management and sponsor oversight of service providers ³. Check the current step and adoption status on ICH's own guideline page, and check with counsel before treating any of this as a regulatory position for your programs.

Which Backgrounds Produce This Person?

Most of them come out of clinical operations or biometrics: a study lead, a head of feasibility, a director of clinical data management who spent two years teaching themselves what a model can and cannot be asked. A smaller group comes from medical affairs or from CRO delivery leadership, where the pressure to compress timelines is constant and visible. What they share is having personally owned a date that slipped.

The unexpected backgrounds are worth opening the search to. Pharmacovigilance signal detection produces people who have lived for years with false positives, a threshold nobody agrees on, and an inspector at the end of it, which is most of this job's emotional content. Regulatory writing produces people who already work at the boundary where a generated draft has to become a defensible document, and that lane now has its own hire in the form of an AI-assisted regulatory medical writer. Standards work, CDISC mapping and legacy data conversion, produces people who understand that most of the promised speed dies in the data, not in the model.

The background that rarely works on its own is the pure research ML scientist who has never sat through an inspection or watched a protocol amendment consume nine weeks. They are essential on the team and expensive as the owner. The other near miss is a platform engineer whose AI experience is entirely infrastructure.

One genuinely transferable outside profile: someone who has run an AI program in another regulated setting, where the audience for the evidence was an auditor rather than a dashboard. The closest published sibling is the construction AI innovation program manager. Do not hire that person to write your protocol, but do interview them for how they held a program together when the evidence had to survive somebody hostile.

Ask How They Used AI on Their Own Protocol Work

The candidates who are good at this got good by using assistants on work they owned, then finding out where it broke. Concretely: drafting inclusion and exclusion criteria from a synopsis and then checking every one against source guidance; summarizing two hundred monitoring visit reports and then hand-auditing a sample of twenty to see what the summary flattened; writing a feasibility query in a language they do not really write, then getting a statistician to tear it apart.

That history is interviewable. Ask them to walk you through one session in detail: what they asked for first, what came back wrong, and how they found out it was wrong. Strong answers are unglamorous and specific, and what you are grading is the shape rather than the story. Two shapes that qualify: a fabricated reference caught because the journal volume did not exist that year, and a summary of site issues that silently dropped every case the site had already fixed, which inverted the ranking. Neither of those can be produced by someone who has only evaluated a tool, which is why the question works.

The anti-tell is a candidate whose entire AI experience is procurement: a vendor evaluation run, a working group chaired, a policy written. That is real work and it is not this work. If nothing they describe involves them personally checking a model's output against something outside the conversation, they will not notice when your study teams stop checking either.

One more question worth asking: what would you refuse to hand to a model in a trial. A candidate with no answer has not thought about it. A candidate with a long list has not used one.

Where Do You Find Them, and What Closes Them?

Start inside your own company. In most sponsors this person is already running a study or a data function and has been doing an unpaid version of the job for a year. The external pool is thin, and the visible external market today is a handful of large sponsors.

AstraZeneca was recruiting a director-level business partner into a standing AI for Clinical Development team in Gaithersburg in August 2026, and that posting was fetched and read for this piece ¹. Two others turned up in the same sweep and were not: a Pfizer Head of AI Clinical Excellence scoped across the clinical development lifecycle, and an AbbVie director-level AI strategy role spanning discovery through development. Take those two as leads to verify rather than as evidence, and note that postings close. Three of them is a category forming, not a category formed.

The venues where these people actually are, rather than where recruiters look: the DIA Global Annual Meeting, SCOPE Summit for clinical operations executives, the SCDM annual conference for the data side, CDISC Interchange for the standards side, and TransCelerate BioPharma working groups, whose membership rosters are a directory of people already doing cross-sponsor process work.

What closes them is the decision right rather than the title. The offer that wins says which decisions this person makes alone, which budget line they hold, and who they escalate to when a study team disagrees. The offer that loses puts the role under IT with a dotted line to clinical development and no authority over a protocol, which every serious candidate reads correctly in the first call. Be ready to answer one question directly: what happens the first time this person says a proposed AI use is not adequately evidenced and a program lead overrules them.

Also understand what you are competing with. Most strong candidates are already on a promotion track inside a sponsor, so the alternative to your offer is their existing career, with less risk attached, rather than another AI role.

What Band Does This Role Hire Against, and Where Does It Sit?

Hire it against your existing director or senior director clinical development band, because director is the level the posting evidence actually shows ¹, and because the accountability is a development leadership accountability rather than a technical one. There is no separate market band for this title yet, and a category with a handful of public postings cannot produce a credible point estimate. If you see one quoted, ask what it was built from.

The macro direction is real even where the specific number is not. PwC's 2026 AI Jobs Barometer reports an average wage premium of 62% for roles requiring AI skills across roughly a billion job advertisements ². That is a whole-market average across every occupation, so treat it as evidence that the premium exists rather than as a figure to put in an offer letter for a pharma leadership role. The honest internal framing is simpler: this is a development leadership hire with a scarce combination, so budget at the top of that band and expect a counteroffer from the internal track the candidate is leaving.

On location, expect hybrid rather than remote, typically three days a week in a clinical development hub. The postings sit in the same places as clinical development leadership, starting with the AstraZeneca hub in Gaithersburg ¹. The strategy half of the work travels fine. The conduct half does not, because the person needs to be in the room when a study team decides whether to believe a model, and because inspection readiness and data residency conversations happen with the same people repeatedly.

Write the scope before the title. The titles in this category disagree with each other today, and the scope is the thing a candidate is actually deciding about.

See the benchmarks >